JP2023542066A5 - - Google Patents
Info
- Publication number
- JP2023542066A5 JP2023542066A5 JP2022580316A JP2022580316A JP2023542066A5 JP 2023542066 A5 JP2023542066 A5 JP 2023542066A5 JP 2022580316 A JP2022580316 A JP 2022580316A JP 2022580316 A JP2022580316 A JP 2022580316A JP 2023542066 A5 JP2023542066 A5 JP 2023542066A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical product
- product according
- hydrogen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025258116A JP2026048860A (ja) | 2020-06-24 | 2025-12-17 | 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043498P | 2020-06-24 | 2020-06-24 | |
| US63/043,498 | 2020-06-24 | ||
| PCT/IB2021/055548 WO2021260579A1 (en) | 2020-06-24 | 2021-06-23 | Combination of antibody-drug conjugate and atr inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025258116A Division JP2026048860A (ja) | 2020-06-24 | 2025-12-17 | 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542066A JP2023542066A (ja) | 2023-10-05 |
| JP2023542066A5 true JP2023542066A5 (https=) | 2024-06-25 |
| JP7793556B2 JP7793556B2 (ja) | 2026-01-05 |
Family
ID=76730926
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580316A Active JP7793556B2 (ja) | 2020-06-24 | 2021-06-23 | 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ |
| JP2025258116A Pending JP2026048860A (ja) | 2020-06-24 | 2025-12-17 | 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025258116A Pending JP2026048860A (ja) | 2020-06-24 | 2025-12-17 | 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230330243A1 (https=) |
| EP (1) | EP4171650A1 (https=) |
| JP (2) | JP7793556B2 (https=) |
| KR (1) | KR20230043109A (https=) |
| CN (1) | CN116635082A (https=) |
| AU (1) | AU2021298251A1 (https=) |
| BR (1) | BR112022026205A2 (https=) |
| CA (1) | CA3183867C (https=) |
| IL (1) | IL299368A (https=) |
| MX (1) | MX2022016375A (https=) |
| TW (1) | TW202216208A (https=) |
| WO (1) | WO2021260579A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2024214685A1 (https=) * | 2023-04-10 | 2024-10-17 | ||
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025083069A1 (en) * | 2023-10-16 | 2025-04-24 | Hummingbird Bioscience Pte. Ltd. | Her2-binding molecules |
| WO2025083071A2 (en) * | 2023-10-16 | 2025-04-24 | Hummingbird Bioscience Pte. Ltd. | Antibody-drug conjugates |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| IN2014DN06806A (https=) | 2012-02-10 | 2015-05-22 | Univ Maryland | |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| IL310627B2 (en) * | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| TW202532104A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
| WO2020078905A1 (en) | 2018-10-15 | 2020-04-23 | Merck Patent Gmbh | Combination therapy utilizing dna alkylating agents and atr inhibitors |
-
2021
- 2021-06-23 IL IL299368A patent/IL299368A/en unknown
- 2021-06-23 CN CN202180050401.6A patent/CN116635082A/zh active Pending
- 2021-06-23 EP EP21736708.5A patent/EP4171650A1/en active Pending
- 2021-06-23 JP JP2022580316A patent/JP7793556B2/ja active Active
- 2021-06-23 KR KR1020237002457A patent/KR20230043109A/ko active Pending
- 2021-06-23 BR BR112022026205A patent/BR112022026205A2/pt unknown
- 2021-06-23 MX MX2022016375A patent/MX2022016375A/es unknown
- 2021-06-23 US US18/012,705 patent/US20230330243A1/en active Pending
- 2021-06-23 AU AU2021298251A patent/AU2021298251A1/en active Pending
- 2021-06-23 WO PCT/IB2021/055548 patent/WO2021260579A1/en not_active Ceased
- 2021-06-23 CA CA3183867A patent/CA3183867C/en active Active
- 2021-06-23 TW TW110122959A patent/TW202216208A/zh unknown
-
2025
- 2025-12-17 JP JP2025258116A patent/JP2026048860A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023542066A5 (https=) | ||
| JP2023539715A5 (https=) | ||
| JP2025041725A5 (https=) | ||
| JP2023545096A5 (https=) | ||
| JPWO2020122034A5 (https=) | ||
| JPWO2020130125A5 (https=) | ||
| JP2020019787A5 (https=) | ||
| JP2023070678A5 (https=) | ||
| JP2025160318A5 (https=) | ||
| FI4516357T3 (fi) | Kasvaimen kasvua estävä yhdiste ja menetelmä sen valmistamiseksi ja sen käyttö | |
| JP2024533356A5 (https=) | ||
| JP2018525354A5 (https=) | ||
| JP2017186337A5 (https=) | ||
| JP2020525542A5 (https=) | ||
| RU2017139490A (ru) | Конъюгаты лекарственных средств, содержащие антитела против клаудина 18.2 | |
| TW202028212A (zh) | Ｓｔｉｎｇ促效化合物 | |
| JP2010535713A5 (https=) | ||
| JP2016528251A5 (https=) | ||
| JP2011519941A5 (https=) | ||
| JP2018537975A5 (https=) | ||
| JP2020509027A5 (https=) | ||
| JP2008500815A5 (https=) | ||
| JP2023500875A5 (https=) | ||
| JP2024547111A5 (https=) | ||
| JP2020500834A5 (https=) |